Article Details

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready ...

Retrieved on: 2021-06-01 07:52:30

Tags for this article:

Click the tags to see associated articles and topics

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready .... View article details on hiswai:

Excerpt

KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin's patented POTELLIGENT® ...

Article found on: www.kpvi.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up